Objectives: To analyze the outcomes of cytoreductive surgery and HIPEC in patients with peritoneal carcinomatosis front ovarian cancerMethods: Fifty-three patients with peritoneal carcinomatosis from primary (45 cases) and recurrent (8 cases) ovarian cancer were previously treated by systemic chemotherapy with platinum and taxanes and then submitted to surgical cytoreduction and HIPEC (cisplatin and mitomycin-C) with a closed abdomen technique. The median follow-up period was 27 months (range. 3-107)Results: At the end of operation a complete cytoreduction (CCR-0) was obtained in 37 patients (70%) Major morbidity occurred in 12 patients (23%), reoperation was necessary in 2 patients (4%). and no postoperative mortality was observed Overall 5-year survival probability was 55%, it was 71% in CCR-0, 44% in CCR-1. and none in patients with CCR-2 or CCR-3 residual tumor (log-rank test P = 0.017). The cumulative risk of recurrence in 37 CCR-0 cases was 54% at 5 years from operation.Conclusions: The results of our study indicate the feasibility and the potential benefit of a protocol including systemic chemotherapy, surgical cytoreduction and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer A phase III trial to compare this approach with conventional treatment is needed J. Surg. Oncol. 2010:102:663-670. (C) 2010 Wiley-Liss, Inc.

Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer

Pedrazzani, Corrado;
2010-01-01

Abstract

Objectives: To analyze the outcomes of cytoreductive surgery and HIPEC in patients with peritoneal carcinomatosis front ovarian cancerMethods: Fifty-three patients with peritoneal carcinomatosis from primary (45 cases) and recurrent (8 cases) ovarian cancer were previously treated by systemic chemotherapy with platinum and taxanes and then submitted to surgical cytoreduction and HIPEC (cisplatin and mitomycin-C) with a closed abdomen technique. The median follow-up period was 27 months (range. 3-107)Results: At the end of operation a complete cytoreduction (CCR-0) was obtained in 37 patients (70%) Major morbidity occurred in 12 patients (23%), reoperation was necessary in 2 patients (4%). and no postoperative mortality was observed Overall 5-year survival probability was 55%, it was 71% in CCR-0, 44% in CCR-1. and none in patients with CCR-2 or CCR-3 residual tumor (log-rank test P = 0.017). The cumulative risk of recurrence in 37 CCR-0 cases was 54% at 5 years from operation.Conclusions: The results of our study indicate the feasibility and the potential benefit of a protocol including systemic chemotherapy, surgical cytoreduction and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer A phase III trial to compare this approach with conventional treatment is needed J. Surg. Oncol. 2010:102:663-670. (C) 2010 Wiley-Liss, Inc.
2010
primary ovarian cancer
cytoreductive surgery
HIPEC
intraperitoneal chemotherapy
neoadjuvant chemotherapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma
Chemotherapy, Cancer, Regional Perfusion
Combined Modality Therapy
Female
Humans
Hyperthermia, Induced
Injections, Intraperitoneal
Middle Aged
Ovarian Neoplasms
Peritoneal Neoplasms
Recurrence
Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1029682
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 55
social impact